Silver Book Fact

Anti-VEGF Letter Improvement

Fact image

An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.

Brown D, Nguyen Q, Marcus D, et al. Long-Term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-month results from two phase III trials: RISE and RIDE. Ophthalmol. 2013. http://www.aaojournal.org/article/S0161-6420(13)00212-1/abstract. Accessed May 17, 2016

Reference

Title
Long-Term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-month results from two phase III trials: RISE and RIDE
Publication
Ophthalmol
Publication Date
2013
Authors
Brown D, Nguyen Q, Marcus D, et al
Volume & Issue
Volume 120, Issue 10
Pages
324-30
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • During the first year of a community pharmacy services program in 2003 which included 256 diabetes patients who used scheduled consultations, clinical goal setting, monitoring and collaborative drug therapy management…  
  • Improved control of cholesterol or blood lipids, can reduce diabetic complications by 20-50%.  
  • Blood pressure control reduces the risk of cardiovascular disease (heart disease or stroke) among people with diabetes by 33% to 50%, and the risk of microvascular complications (eye, kidney, and…  
  • Economics of DR Treatment
    Laser treatment plus a VEGF inhibitor achieved an incremental cost-effectiveness ratio of $12,410 per quality adjusted life year in patients with DME.  
  • An evaluation of the Diabetes Prevention Program lifestyle intervention found that providing this intervention at age 50 could prevent 37% of new cases of diabetes before age 65. If Medicare…